A GLOBAL MARKET - A GLOBAL INDUSTRY

8 - 10 December 2008

 

Organised by the Members of IGPA: 

 CGPA | EGA | GPhA | IPA | JGA

 

Pre-conference Seminar:

 US GENERICS FROM DIFFERENT INDUSTRY PERSPECTIVES

8 December 2008

Organised by Greenblum & Bernstein

 

INTERCONTINENTAL HOTEL | GENEVA | SWITZERLAND

 

CONFERENCE TOPICS

Key Developments in Intellectual Property Affecting Access to Generic Medicines

* Patent Linkage. Comparing different applications of “patent linkage” and how these affect access to generic medicines

* Data Exclusivity vs Data Protection (Article 39.3 TRIPS): understanding the differences between these concepts and their impact on generic competition in developing countries

* Intellectual property enforcement measures: when legitimate measures to protect innovation can be misused as barriers to generic competition

 

Developments in Generic Medicines Markets Worldwide: Asia and India

* Impact of changes in regulatory infrastructure on the healthcare industry in India

* Have recent government polices to stimulate the uptake of generic medicines in Japan been successful?

* What has been the impact of rapid economic change in China on the local generic medicines market?

 

Developments in Generic Medicines Markets Worldwide: Europe and North America

* Current developments in the USA impacting the generic medicines industry

* Threats and opportunities in a rapidly changing European generics market

* Changes in government reimbursement for generic medicines: A Canadian case study

 

Developments in Generic Medicines Markets Worldwide

* How have regulatory and IP developments affected the development of the generic markets in the other regions of the world?

 

Market Dynamics

* Overview of the global generic pharmaceutical market

* Key market dynamics for the generic medicines industry: strategic developments

 

Regulatory Developments Impacting on the Business of Generic Medicines Companies 

* WHO prequalification of medicines programme: opportunities for generic medicines manufacturers

* GMP/GCP/GLP inspections developments

* ICH Quality Topics Q8, Q9, Q10: new opportunities for generic manufacturers?

* New developments in the use of TRIPS flexibilities for fostering the production of essential medicines / Case Study: The German government’s programme on TRIPS and pharmaceutical production in developing countries

 

CEO Panel

 

CONFIRMED SPEAKERS

Pascal Lamy, Director General, World Trade Organization (WTO) | Greg Perry, Director General, European Generic medicines Association (EGA) | Yehudah Livneh, Chairman of IGPA IP Committee | Michelle Childs, Head of European Affairs, Knowledge Ecology International (KEI) | Christoph Spennemann, Legal expert, United Nations Conference on Trade and Development (UNCTAD) | Julia Pike, Intellectual Property Director & Counsel, Hospira Global Pharma R&D | Roger Kampf, Counsellor, Intellectual Property Division, WTO | German Velasquez, Director, WHO Secretariat on Public Health, Innovation and Intellectual Property | Dilip Shah, Secretary-General, Indian Pharmaceutical Alliance (IPA) | Surinder Singh, Drugs Controller General, Indian Government | Kenichi Nagano, Director General, Japan Generic medicines Association (JGA) | Mandy Chui, Country Principal China Consulting & Services, IMS Health | Kathleen Jaeger, President & CEO, Generic Pharmaceutical Association (GPhA) | Eric Gorka, President, European Generic medicines Association (EGA) | Allan Oberman, Chairman, Canadian Generic Pharmaceutical Association (CGPA) | Jim Keon, President, Canadian Generic Pharmaceutical Association (CGPA) | Lina Owais, Deputy General Director, Jordanian Assoc. of Pharma. Manufacturers (JAPM) | Skhumbuzo G. Ngozwana, Chairman, National Association of Pharmaceutical Manufacturers (NAPM) | Odnir Finotti, Vice President, Pró Genéricos (Brazil) | Alan Sheppard, Global Head Generics, IMS Health | Vijay P. Karwal, Managing Director, Healthcare Banking Group, The Royal Bank of Scotland (RBS) | Nicholas Cappuccino, Chairman of IGPA Science Committee | Lembit Rägo, Head of WHO Quality Assurance & Safety: Medicines Unit, Department of Medicines Policy and Standards | Frank Schmiedchen, Governmental Director IP Rights, Federal Ministry for Economic Cooperation & Development of Germany | Andreas Rummelt, CEO, Sandoz | Pankaj Patel, CEO, Cadila Healthcare | Francis Gurry, Director General of the World Intellectual Property Organization (WIPO)

 

 

 

NETWORKING EVENTS

Welcome Cocktail

Welcome Coffees & Coffee Breaks

Networking Buffet Lunches

Cocktail & Conference Dinner 

End-of-Conference Farewell Drinks

 

PLATINUM SPONSOR

Barr Pharmaceuticals 

 

SEMINAR SPONSOR

Greenblum & Bernstein 

 

EVENT SPONSOR

IMS Health

 

SILVER SPONSOR

Winston & Strawn LLP